Valuation: ALLOVIRPAR

Market Cap 4.92Cr 4.28Cr 3.98Cr 3.66Cr 6.9Cr 469.77Cr 7.01Cr 47Cr 18Cr 233.87Cr 18Cr 18Cr 784.22Cr P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -6.91Cr -6Cr -5.59Cr -5.13Cr -9.69Cr -659.42Cr -9.84Cr -66Cr -26Cr -328.29Cr -26Cr -25Cr -1.1TCr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day+0.14%
Current month-64.68%
Current year-64.68%
3 years 3.4
Extreme 3.4001
86.25
5 years 3.4
Extreme 3.4001
607.43
10 years 3.4
Extreme 3.4001
1,126.08

Financials

2023 2024
Net sales - -
Net income -19Cr -17Cr -15Cr -14Cr -27Cr -1.82TCr -27Cr -181.61Cr -71Cr -904.95Cr -72Cr -70Cr -3.03TCr -5.88Cr -5.11Cr -4.76Cr -4.37Cr -8.24Cr -561.01Cr -8.37Cr -56Cr -22Cr -279.3Cr -22Cr -22Cr -936.53Cr
Net Debt -16Cr -14Cr -13Cr -12Cr -22Cr -1.49TCr -22Cr -149.28Cr -59Cr -743.82Cr -59Cr -57Cr -2.49TCr -12Cr -10Cr -9.57Cr -8.79Cr -17Cr -1.13TCr -17Cr -112.82Cr -44Cr -562.16Cr -44Cr -43Cr -1.89TCr
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change Volume
31/26/31 $3.465 -0.43% 34,675
30/26/30 $3.480 +2.35% 76,286
29/26/29 $3.400 +1.80% 1,00,019
28/26/28 $3.340 -6.70% 1,18,283
27/26/27 $3.580 -4.02% 71,676
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock